Search Results - Robert W. Chandler
- Showing 1 - 3 results of 3
-
1
-
2
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency by Zafeiris Zafeiriou, Diletta Bianchini, Robert W. Chandler, Pasquale Rescigno, Wei Yuan, Suzanne Carreira, Maialen Barrero, Antonella Petremolo, Susana Miranda, Ruth Riisnaes, Daniel Nava Rodrigues, Bora Gürel, Semini Sumanasuriya, Alec Paschalis, Adam Sharp, Joaquı́n Mateo, Nina Tunariu, Arul M. Chinnaiyan, Colin C. Pritchard, Kevin Kelly, Johann S. de Bono
Published 2018Artigo -
3
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial by Joaquı́n Mateo, Núria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert J. Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese, Omi Parikh, Simon J. Crabb, Angus Robinson, Duncan B. McLaren, Alison Birtle, Jacob Tanguay, Susana Miranda, Ines Figueiredo, George Seed, Cláudia Bertan, Penny Flohr, Berni Ebbs, Pasquale Rescigno, Gemma Fowler, Ana Ferreira, Ruth Riisnaes, Rita Pereira, Andra Curcean, Robert W. Chandler, Matthew Clarke, Bora Gürel, Mateus Crespo, Daniel Nava Rodrigues, Shahneen Sandhu, Aude Espinasse, Peter Chatfield, Nina Tunariu, Wei Yuan, Emma Hall, Suzanne Carreira, Johann S. de Bono
Published 2019Artigo
Search Tools:
Related Subjects
Biology
Genetics
Cancer
DNA
Gene
Internal medicine
Medicine
Oncology
Poly ADP ribose polymerase
Polymerase
Prostate cancer
Cancer research
Carboplatin
Chemotherapy
Cisplatin
DNA repair
Flow cytometry
Homologous recombination
Mitochondrial DNA
Molecular biology
Nuclear DNA
Olaparib
Open label
PARP inhibitor
Prostate
Randomized controlled trial
Urology